Neuroblastoma

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78.

Abstract

Neuroblastoma is the most common extracranial solid tumour occurring in childhood and has a diverse clinical presentation and course depending on the tumour biology. Unique features of these neuroendocrine tumours are the early age of onset, the high frequency of metastatic disease at diagnosis and the tendency for spontaneous regression of tumours in infancy. The most malignant tumours have amplification of the MYCN oncogene (encoding a transcription factor), which is usually associated with poor survival, even in localized disease. Although transgenic mouse models have shown that MYCN overexpression can be a tumour-initiating factor, many other cooperating genes and tumour suppressor genes are still under investigation and might also have a role in tumour development. Segmental chromosome alterations are frequent in neuroblastoma and are associated with worse outcome. The rare familial neuroblastomas are usually associated with germline mutations in ALK, which is mutated in 10-15% of primary tumours, and provides a potential therapeutic target. Risk-stratified therapy has facilitated the reduction of therapy for children with low-risk and intermediate-risk disease. Advances in therapy for patients with high-risk disease include intensive induction chemotherapy and myeloablative chemotherapy, followed by the treatment of minimal residual disease using differentiation therapy and immunotherapy; these have improved 5-year overall survival to 50%. Currently, new approaches targeting the noradrenaline transporter, genetic pathways and the tumour microenvironment hold promise for further improvements in survival and long-term quality of life.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis
  • Biomarkers / blood
  • Dopamine / analysis
  • Dopamine / blood
  • Homovanillic Acid / analysis
  • Homovanillic Acid / blood
  • Humans
  • Incidence
  • Mutation / genetics
  • Mutation / physiology
  • N-Myc Proto-Oncogene Protein / analysis
  • N-Myc Proto-Oncogene Protein / blood
  • Neuroblastoma / complications*
  • Neuroblastoma / epidemiology
  • Neuroblastoma / physiopathology*
  • Remission, Spontaneous
  • Vanilmandelic Acid / analysis
  • Vanilmandelic Acid / blood

Substances

  • Biomarkers
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Vanilmandelic Acid
  • Dopamine
  • Homovanillic Acid